1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CA87261EBD7FEFE685258473002682CD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-use-of-technology-current-trends-future-directions-united-states?opendocument
18
19opendocument
2018.205.176.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions in the United States

ID: 5578


Features:

16 Info Graphics

4 Data Graphics

50+ Metrics

7 Narratives


Pages/Slides: 28


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions in the United States”

STUDY OVERVIEW


As treatment options in the United States become more complex and plentiful, patient advocacy groups play a vital role in educating patients about new therapies and medical breakthroughs. While pharma companies seek to identify patient advocacy groups that align best with their therapeutic areas, it is also important to know the social platforms advocacy groups are using to deliver patient education. Likewise, pharma advocacy groups need to continually be aware of current and emerging trends in patient advocacy to be effective partners.

Best Practices, LLC undertook this benchmarking research to examine the winning strategies and best practices in patient advocacy in the United States. In particular, this study identifies effective platforms for delivering education to patient groups, and current and emerging trends in patient advocacy in the United States.

KEY TOPICS

  • Understanding the advocacy landscape
  • Effective platforms to deliver education to patient groups
  • Current issues surrounding patient advocacy
  • Future directions

KEY METRICS
  • What current factors in the marketplace do you feel should receive the greatest consideration with respect to patient advocacy issues?
  • Please rate the importance of the listed platforms in delivering education to patient groups

SAMPLE KEY FINDINGS
  • New technologies for patient education: Video sites, social networks, professional networks, and podcasts have created new channels and opportunities for pharma and external advocacy groups to educate patients. This study reveals that nearly 80% of participants rated social network groups like Facebook and YouTube & other video sites as important.

METHODOLOGY

Best Practices, LLC engaged 48 leaders supporting patient advocacy initiatives at 43 biopharmaceutical companies in the United States through a benchmarking survey.


Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; Blue Earth Diagnostics; Boehringer Ingelheim; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; Natera; Novartis; Novo Nordisk; OTSUKA; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Spark Therapeutics; Theravance; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.